1. In Vivo

From The Foundry, an Incubator Focused on Ophthalmology

The Foundry has created a new incubator to focus on ophthalmology, Forsight Labs, in partnership with Eugene de Juan, MD, a leading ophthalmologist and serial entrepreneur, who was one of the founders of Second Sight, and InnoRx.

Two years ago, executives from venture capital firm Morgenthaler Ventures and medical device incubator The Foundry flew across the country to talk to officials from the Naval Research Laboratories (NRL) in Washington, DC. "The NRL has a silicon foundry that was doing interesting work in producing a silicon matrix that could be implanted in the retina to restore vision for those who had lost their sight," recalls Robin Bellas, a partner at Morgenthaler.

The idea was to launch a company from The Foundry, to be called Percept, but Morgenthaler and The Foundry decided...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 
• By Bridget Silverman

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By Jo Shorthouse

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.